For Immediate Release - February 5, 2004

"We are delighted with our new arrangement with Del Global," said Jack W. Cumming, Chairman and Chief Executive Officer of Hologic. "This licensing agreement recognizes the strength of each company and represents a positive, mutually beneficial business solution for both parties."

"We are very pleased with this agreement. The Hologic product family has proven an excellent choice for many general radiography customers, and it will enhance our offering considerably. We look forward to providing these systems and further developing their capabilities," said Walter Schneider, President and CEO of Del Global Technologies.

This News Release contains forward-looking information that involves risks and uncertainties, including statements about Hologic's and Del Global's plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding the relationship and anticipated benefits and business solutions that may result from Hologic's licensing agreement with Del Global. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Factors that could cause actual results to materially differ include, without limitation, Hologic's and Del Global's limited experience in working together. Hologic cannot assure that Del Global will be able to exploit successfully the technology licensed to it, including without limitation, as a result of uncertainties inherent in the development of new products and the enhancement of existing products, including technical and regulatory risks, cost overruns and delays; the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated; Del Global's ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the early stage of market development for digital x-ray products; manufacturing risks that may limit Hologic's or Del Global's ability to ramp-up commercial production of the components and systems contemplated by this arrangement, including Hologic's reliance on a single source of supply for some key components of its DirectRay detector as well as the need to comply with especially high standards for those components and in the manufacture of digital x-ray products in general; technical innovations that could render products marketed or under development by Hologic obsolete; competition; and reimbursement policies for the use of Del Global's products. Other factors that could adversely affect Hologic's and Del's respective businesses and prospects are described in their respective filings with the Securities and Exchange Commission. Hologic and Del expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Hologic's or Del's respective expectations or any change in events, conditions or circumstances on which any such statement is based.